Michael Hallek to Europe
This is a "connection" page, showing publications Michael Hallek has written about Europe.
Connection Strength
0.015
-
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol. 2019 06 01; 37(16):1391-1402.
Score: 0.015
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.